Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $8
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $6 to $8.
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $6 to $8.